It has recently been acknowledged that classical immunotherapy sensitivity biomarkers such as tumor mutation burden and PD-L1 expression have limited predictive value in mesothelioma immunotherapy (reviewed in [111]). The gene discussed is CD274; the disease is mesothelioma.